Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

2:29am IST
Change (% chg)

$0.05 (+3.03%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Athersys reports Q3 loss per share $0.06
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Athersys Inc :Athersys reports third quarter 2017 results.Q3 loss per share $0.06.Q3 revenue $400,000 versus $300,000.Q3 revenue view $598,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Athersys and Nikon Cell Innovation to collaborate on MultiStem manufacturing in Japan
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Athersys Inc ::Athersys and Nikon Cell Innovation to collaborate on multistem commercial manufacturing in Japan.Athersys - entered manufacturing services agreement with Nikon Cell for commercial production of its stem cell therapy in Japan for ischemic stroke.Athersys - technology transfer of stem cell production methods in preparation for potential commercialization in Japan after treasure clinical study.  Full Article

Athersys, FDA agree on design for ischemic stroke late-stage study
Wednesday, 28 Sep 2016 

Athersys Inc :Athersys receives FDA agreement under special protocol assessment for phase 3 study of multistem® treatment for ischemic stroke.  Full Article

Athersys qtrly loss per share $0.08
Wednesday, 10 Aug 2016 

Athersys Inc : Athersys reports second quarter 2016 results . Q2 revenue $600,000 versus $200,000 .Qtrly loss per share $0.08.  Full Article

HEALIOS and Athersys sign licensing contract
Friday, 8 Jan 2016 

HEALIOS K.K:Signed licensing contract with Athersys, on MultiStem.To pay $15 mln upfront to Athersys and sees to pay up to $30 mln in total as milestone payments.  Full Article

BRIEF-Athersys reports Q3 loss per share $0.06

* Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: